Reviewing Elevai Labs (NASDAQ:ELAB) & Arvinas (NASDAQ:ARVN)

Elevai Labs (NASDAQ:ELAB) and Arvinas (NASDAQ:ARVN) are both small-cap multi-sector conglomerates companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Valuation & Earnings

This table compares Elevai Labs and Arvinas”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elevai Labs	$2.45 million	0.99	-$4.30 million	($433.87)	-0.01
Arvinas	$263.40 million	2.20	-$198.90 million	($2.77)	-3.04

Elevai Labs has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elevai Labs and Arvinas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elevai Labs	-223.41%	-124.93%	-85.10%
Arvinas	-75.51%	-33.75%	-16.75%

Insider and Institutional Ownership

22.2% of Elevai Labs shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 0.6% of Elevai Labs shares are owned by insiders. Comparatively, 5.2% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Elevai Labs has a beta of -2.93, indicating that its stock price is 393% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Elevai Labs and Arvinas, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elevai Labs	0	0	0	0	0.00
Arvinas	0	5	11	0	2.69

Arvinas has a consensus target price of $37.47, suggesting a potential upside of 344.44%. Given Arvinas’ stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Elevai Labs.

Summary

Arvinas beats Elevai Labs on 12 of the 14 factors compared between the two stocks.

About Elevai Labs

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.